

## 2024 Current Fiscal Year Report: Cures Acceleration Network Review Board

Report Run Date: 04/19/2024 11:29:56 AM

### 1. Department or Agency

Department of Health and Human Services

### 2. Fiscal Year

2024

### 3. Committee or Subcommittee

Cures Acceleration Network Review Board

### 3b. GSA Committee No.

79631

### 4. Is this New During Fiscal Year? 5. Current Charter 6. Expected Renewal Date 7. Expected Term Date

No 02/07/2022 02/07/2024

### 8a. Was Terminated During Fiscal Year?

No

### 8b. Specific Termination Authority

### 8c. Actual Term Date

### 9. Agency Recommendation for Next Fiscal Year

Continue

### 10a. Legislation Req to Terminate?

Not Applicable

### 10b. Legislation Pending?

Not Applicable

### 11. Establishment Authority Statutory (Congress Created)

### 12. Specific Establishment Authority

42 U.S.C. 287a(d)

### 13. Effective Date

03/23/2010

### 14. Committee Type

Continuing

### 14c. Presidential?

No

### 15. Description of Committee Scientific Technical Program

Advisory Board

### 16a. Total Number of Reports

No Reports for this Fiscal Year

### 17a. Open 0 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 0

### Meetings and Dates

No Meetings

	Current FY	Next FY
<b>18a(1). Personnel Pmts to Non-Federal Members</b>	\$0.00	\$0.00
<b>18a(2). Personnel Pmts to Federal Members</b>	\$0.00	\$0.00
<b>18a(3). Personnel Pmts to Federal Staff</b>	\$0.00	\$0.00
<b>18a(4). Personnel Pmts to Non-Member Consultants</b>	\$0.00	\$0.00
<b>18b(1). Travel and Per Diem to Non-Federal Members</b>	\$0.00	\$0.00
<b>18b(2). Travel and Per Diem to Federal Members</b>	\$0.00	\$0.00
<b>18b(3). Travel and Per Diem to Federal Staff</b>	\$0.00	\$0.00
<b>18b(4). Travel and Per Diem to Non-member Consultants</b>	\$0.00	\$0.00
<b>18c. Other(rents,user charges, graphics, printing, mail, etc.)</b>	\$0.00	\$0.00
<b>18d. Total</b>	\$0.00	\$0.00
<b>19. Federal Staff Support Years (FTE)</b>	0.00	0.00

**20a. How does the Committee accomplish its purpose?**

This committee is composed of highly qualified scientists and public representatives with expertise related to the interests of the Center. It provides a breadth and balance of specialized knowledge necessary to assess the long-range goals, program concepts, research opportunities, and direction of ongoing research and future plans.

**20b. How does the Committee balance its membership?**

The Cures Acceleration Network Review Board,

NCATS, consists of 24 appointed members who were selected based on the following requirements: (1) for each of the fields of (a) basic research, (b) medicine, (c) biopharmaceuticals, (d) discovery and delivery of medical products, (e) bioinformatics and gene therapy, (f) medical instrumentation, and (g) regulatory review and approval of medical products, the Secretary will select at least 1 individual who is eminent in such fields; (2) at least 4 individuals will be recognized leaders in professional venture capital or private equity organizations and have demonstrated experience in private equity investing; and (3) at least 8 individuals will represent disease advocacy organizations. In addition, the Secretary will appoint as ex officio members of the Board (1) a representative of the NIH, recommended by the Secretary; (2) a representative of the Office of the Assistant Secretary of Defense for Health Affairs, recommended by the Secretary of Defense; (3) a representative of the Office of the Under Secretary for Health for the Veterans Health Administration, recommended by the Secretary of Veterans Affairs; (4) a representative of the National Science Foundation, recommended by the Chair of the National Science Board; and (5) a representative of the Food and Drug Administration, recommended by the Commissioner of Food and Drugs.

**20c. How frequent and relevant are the Committee Meetings?**

The CANRB did not meet in FY 2023.

**20d. Why can't the advice or information this committee provides be obtained elsewhere?**

This committee is composed of recognized experts in basic research, medicine, biopharmaceuticals, discovery and delivery of

medical products, bioinformatics and gene therapy, medical instrumentation, and regulatory review and approval of medical products. There are also members who are recognized leaders in professional venture capital or private equity organizations with demonstrated experience in private equity investing, and members who represent disease advocacy organizations. Their recommendations cannot be obtained from other sources because the complex nature of research requires a specialized balance and breadth of objective expertise not otherwise available.

**20e. Why is it necessary to close and/or partially closed committee meetings?**

N/A

**21. Remarks**

Reports: This committee did not produce any reports this reporting period. The DFO and Decision Maker are the same person, the Director, Office of Grants Management and Scientific Review, based on the assignment of duties within the Center. The Charter allows the Committee to have 29 authorized members including but not limited to SGEs, Ex-Officios, and Representatives (if applicable). There are five Ex-Officios, Dr. Tabak, Dr. Dickinson, Dr. Petro, Dr. Ramoni, and Dr. Weichold, and three appointed Representatives Dr. Reddy, Dr. Rosenblatt, and Dr. Stoner, which equals to the total of 29 Max number of members. Committee staff were working on CANRB with the expectation of holding several meetings in FY2023. Due to changes in institute leadership and ongoing challenges in identifying and appointing a sufficient number of members to reach the statutorily mandated quorum of thirteen members, the CAN Review Board could not be convened in FY23. No Ex

Officio members conducted any work for the committee in FY2023. Chair Andrew Lo was not administratively extended, therefore, there is no chair listed in this report. Representatives Kiran Reddy and Elizabeth Stoner were administratively extended to 04/29/2023. Dr. Lawrence Tabak's title was updated from Performing the Duties of the NIH Director to Acting Director, NIH this fiscal year. Lisa Schill was added to the member list from 07/17/2022 - 10/31/2023.

### **Designated Federal Officer**

ANNA L. RAMSEY-EWING Director, Office of Grants Management and Scientific Review

<b>Committee Members</b>	<b>Start</b>	<b>End</b>	<b>Occupation</b>	<b>Member Designation</b>
Dickinson, Richard	03/01/2021	02/29/2024	Director, National Science Foundation	Ex Officio Member Special Government Employee (SGE) Member
Frost, Simon	01/18/2021	10/31/2024	President, Hope for Annabel Foundation	Special Government Employee (SGE) Member
McVearry, Kelly	08/30/2021	10/31/2024	Chief Executive Officer, The Hypatia Group, Inc.	Special Government Employee (SGE) Member
PETRO, JAMES	09/21/2020	12/31/2026	HUMAN SYSTEMS DIRECTORATE OFFICE OF THE UNDER SECRETARY OF DEFENSE FOR RESEARCH AND ENGINEERING	Ex Officio Member
Ramoni, Rachel	03/01/2021	02/29/2024	Chief Research and Development Officer, US Department of Veterans Affairs	Ex Officio Member Special Government Employee (SGE) Member
Ruediger, Susan	01/18/2022	10/31/2023	Founder and CEO, Charcot Marie Tooth Research Foundation	Special Government Employee (SGE) Member
Schill, Lisa	07/17/2022	10/31/2023	Patient Advocacy Engagement Consultant	Special Government Employee (SGE) Member

Shireman, Paula	06/06/2021	10/31/2024	Professor with Tenure, University of Texas Health Science Center	Special Government Employee (SGE) Member
Summar, Marshall	06/06/2021	10/31/2023	Director, Rare Disease Institute	Special Government Employee (SGE) Member
Tabak, Lawrence	12/21/2021	01/19/2025	Acting Director, National Institutes of Health	Ex Officio Member
Weichold, Frank	03/01/2021	02/28/2024	Director, US Food and Drug Administration	Ex Officio Member
Wheeden, Kristen	01/18/2022	10/31/2024	Executive Director, United Porphyrias Association	Special Government Employee (SGE) Member

**Number of Committee Members Listed: 12**

### Narrative Description

Authorized to reduce significant barriers to successful translation and accelerate the development of high-need cures, the Cures Acceleration Network (CAN) provides the National Center for Advancing Translational Sciences with flexibility in how it funds projects. This authority is guided by the CAN Review Board, which according to its charter, advises and provides recommendations to the NCATS director on the policies, programs and procedures for carrying out the duties of the Office of the Director and on identifying significant barriers to successful translation of basic science into clinical application.

### What are the most significant program outcomes associated with this committee?

Checked if  
Applies

Improvements to health or safety	<input type="checkbox"/>
Trust in government	<input checked="" type="checkbox"/>
Major policy changes	<input type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input type="checkbox"/>

- Improved service delivery ☐
- Increased customer satisfaction ☐
- Implementation of laws or regulatory requirements ☐
- Other ☐

### Outcome Comments

N/A

### What are the cost savings associated with this committee?

Checked if Applies

- None ☐
- Unable to Determine ☒
- Under \$100,000 ☐
- \$100,000 - \$500,000 ☐
- \$500,001 - \$1,000,000 ☐
- \$1,000,001 - \$5,000,000 ☐
- \$5,000,001 - \$10,000,000 ☐
- Over \$10,000,000 ☐
- Cost Savings Other ☐

### Cost Savings Comments

NIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new way to treat and prevent diseases.

### What is the approximate Number of recommendations produced by this committee for the life of the committee?

66

### Number of Recommendations Comments

There were no recommendations for FY2023

### What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

0%

### % of Recommendations Fully Implemented Comments

Information on the research funded by NIH is available through the RePORT (Research

Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>.

**What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?**

0%

#### **% of Recommendations Partially Implemented Comments**

Information on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>.

**Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?**

Yes ☒ No ☐ Not Applicable ☐

#### **Agency Feedback Comments**

Information is provided to the public at each meeting. The public can view information related to the Committee through the committee's official website.

**What other actions has the agency taken as a result of the committee's advice or recommendation?**

Checked if Applies

Reorganized Priorities	<input type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input checked="" type="checkbox"/>

#### **Action Comments**

The Committee advises and provides recommendations to the NCATS director on the policies, programs and procedures for carrying out the duties of the Office of the Director



and on identifying significant barriers to successful translation of basic science into clinical application.

**Is the Committee engaged in the review of applications for grants?**

No

**Grant Review Comments**

N/A

**How is access provided to the information for the Committee's documentation?**

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input type="checkbox"/>
Other	<input checked="" type="checkbox"/>

**Access Comments**

IC Committee Management Officer 240-669-5201